Titre du document / Document title
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis
Auteur(s) / Author(s)
SALVO Virgilo A. (1 2) ;
BOUE Stephen M. (3) ;
FONSECA Juan P. (1 2) ;
ELLIOTT Steven (1 4) ;
CORBITT Cynthia (5) ;
COLLINS-BUROW Bridgette M. (1) ;
CURIEL Tyler J. (1 2) ;
SRIVASTAV Sudesh K. (2 6) ;
SHIH Betty Y. (3) ;
CARTER-WIENTJES Carol (3) ;
WOOD Charles E. (7) ;
ERHARDT Paulw. (8) ;
BECKMAN Barbara S. (2 4 9) ;
MCLACHLAN John A. (2 4 9) ;
CLEVELAND Thomas E. (3) ;
BUROW Matthew E. (1 2 4 9 10) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Section of Hematology and Medical Oncology, Department of Medicine, Tulane University Health Science Center, ETATS-UNIS
(2) The Tulane Cancer Center, Tulane University Health Science Center, ETATS-UNIS
(3) Southern Regional Research Center, U.S. Department of Agriculture, New Orleans, Los Angeles, ETATS-UNIS
(4) The Center for Bioenvironmental Research, Tulane University Health Science Center, ETATS-UNIS
(5) Department of Biology, University of Louisville, Louisville, Kentucky, ETATS-UNIS
(6) Department of Biostatistics, Tulane University Health Science Center, ETATS-UNIS
(7) Department of Pathology/Section on Comparative Medicine,Wake Forest University School of Medicine, Winston -Salem, North Carolina, ETATS-UNIS
(8) Center for Drug Design and Development, University of Toledo, Toledo, Ohio, ETATS-UNIS
(9) Department of Pharmacology, Tulane University Health Science Center, ETATS-UNIS
(10) Department of Surgery, Tulane University Health Science Center, ETATS-UNIS
Résumé / Abstract
Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II, and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4%) and BG-1 cells (-73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.
Revue / Journal Title
Clinical cancer research
ISSN
1078-0432
CODEN CCREF4
Source / Source
2006, vol. 12, n
o23, pp. 7159-7164 [6 page(s) (article)] (30 ref.)
Langue / Language
Anglais
Editeur / Publisher
American Association for Cancer Research, Philadelphia, PA, ETATS-UNIS
(1995)
(Revue)
Mots-clés anglais / English Keywords
;
;
;
;
;
;
;
;
;
;
;
;
Mots-clés français / French Keywords
;
;
;
;
;
;
;
;
;
;
;
;
Mots-clés espagnols / Spanish Keywords
;
;
;
;
;
;
;
;
;
;
;
;
Localisation / Location
INIST-CNRS, Cote INIST : 26073, 35400014510391.0410
Nº notice refdoc (ud4) : 18353411
